Search - tctmd.com

Displaying 21 - 40 of 235

Sort: Relevancy | Date

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Michael O'Riordan

April 25, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Michael O'Riordan

April 25, 2016

News Daily News

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

Michael O'Riordan

April 25, 2016

News Daily News

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

L.A. McKeown

March 08, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

L.A. McKeown

March 08, 2016

News Daily News

女性报告 PCI 术后持续心绞痛多于男性，引发更多问题

L.A. McKeown

March 06, 2016

News Daily News

Women More Often Than Men Report Lingering Angina After PCI, Raising More Questions

L.A. McKeown

March 06, 2016

News Daily News

生物可吸收支架导致装置血栓风险增加，但一些人士表示风险可得到抑制

Michael O'Riordan

February 23, 2016

News Daily News

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Michael O'Riordan

February 23, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

News Daily News

SORT OUT IV at 5 Years: Better Long-term Safety Confirmed for Second Generation Stents

L.A. McKeown

February 16, 2016

News Daily News

5 年时 SORT OUT IV：已证实第二代支架的长期安全性更佳

L.A. McKeown

February 16, 2016

News Daily News

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

L.A. McKeown

February 03, 2016

News Daily News

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

L.A. McKeown

February 03, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

News Conference News TCT 2015

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

Advertisement

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

女性报告 PCI 术后持续心绞痛多于男性，引发更多问题

Women More Often Than Men Report Lingering Angina After PCI, Raising More Questions

生物可吸收支架导致装置血栓风险增加，但一些人士表示风险可得到抑制

Mayor Riesgo de Trombsosis del Dispositivo con Andamiajes Bioabsorbibles Aunque Algunos Riesgos Pueden Mitigarse

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

SORT OUT IV at 5 Years: Better Long-term Safety Confirmed for Second Generation Stents

5 年时 SORT OUT IV：已证实第二代支架的长期安全性更佳

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

TWENTE: ZES, EES Convey Similar Safety, Efficacy Results at 5 Years

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

DAPT Study Subanalysis Focuses on EES Subgroup

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content